nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CHRM3—epilepsy syndrome	0.0598	0.24	CbGaD
Paroxetine—CHRM1—epilepsy syndrome	0.0558	0.224	CbGaD
Paroxetine—panic disorder—Diazepam—epilepsy syndrome	0.0458	0.138	CpDpCtD
Paroxetine—CHRM2—epilepsy syndrome	0.0456	0.183	CbGaD
Paroxetine—bipolar disorder—Lamotrigine—epilepsy syndrome	0.0421	0.127	CpDpCtD
Paroxetine—bipolar disorder—Oxcarbazepine—epilepsy syndrome	0.0421	0.127	CpDpCtD
Paroxetine—bipolar disorder—Topiramate—epilepsy syndrome	0.0358	0.108	CpDpCtD
Paroxetine—endogenous depression—Valproic Acid—epilepsy syndrome	0.0341	0.103	CpDpCtD
Paroxetine—bipolar disorder—Carbamazepine—epilepsy syndrome	0.0319	0.0959	CpDpCtD
Paroxetine—SLC6A4—epilepsy syndrome	0.0297	0.119	CbGaD
Paroxetine—panic disorder—Clonazepam—epilepsy syndrome	0.0277	0.0834	CpDpCtD
Paroxetine—bipolar disorder—Valproic Acid—epilepsy syndrome	0.0271	0.0815	CpDpCtD
Paroxetine—bipolar disorder—Clonazepam—epilepsy syndrome	0.0255	0.0766	CpDpCtD
Paroxetine—HTR2A—epilepsy syndrome	0.0228	0.0914	CbGaD
Paroxetine—CYP2D6—epilepsy syndrome	0.0208	0.0836	CbGaD
Paroxetine—bipolar disorder—Gabapentin—epilepsy syndrome	0.0206	0.0618	CpDpCtD
Paroxetine—ABCB1—epilepsy syndrome	0.0149	0.0597	CbGaD
Paroxetine—CYP2B6—Fosphenytoin—epilepsy syndrome	0.0116	0.0555	CbGbCtD
Paroxetine—CYP2B6—Clobazam—epilepsy syndrome	0.0101	0.0481	CbGbCtD
Paroxetine—CYP2C8—Trimethadione—epilepsy syndrome	0.00935	0.0447	CbGbCtD
Paroxetine—CYP2C8—Fosphenytoin—epilepsy syndrome	0.00879	0.042	CbGbCtD
Paroxetine—CYP2B6—Carbamazepine—epilepsy syndrome	0.00834	0.0399	CbGbCtD
Paroxetine—CYP2B6—Primidone—epilepsy syndrome	0.00778	0.0372	CbGbCtD
Paroxetine—CYP2B6—Phenytoin—epilepsy syndrome	0.00748	0.0358	CbGbCtD
Paroxetine—ABCB1—Levetiracetam—epilepsy syndrome	0.00744	0.0356	CbGbCtD
Paroxetine—CYP2B6—Propofol—epilepsy syndrome	0.00697	0.0334	CbGbCtD
Paroxetine—CYP2B6—Phenobarbital—epilepsy syndrome	0.00667	0.0319	CbGbCtD
Paroxetine—CYP2B6—Midazolam—epilepsy syndrome	0.00657	0.0314	CbGbCtD
Paroxetine—CYP2C9—Trimethadione—epilepsy syndrome	0.00652	0.0312	CbGbCtD
Paroxetine—CYP2B6—Diazepam—epilepsy syndrome	0.00632	0.0302	CbGbCtD
Paroxetine—CYP2C8—Carbamazepine—epilepsy syndrome	0.00632	0.0302	CbGbCtD
Paroxetine—CYP2C9—Fosphenytoin—epilepsy syndrome	0.00613	0.0293	CbGbCtD
Paroxetine—CYP2C8—Primidone—epilepsy syndrome	0.0059	0.0282	CbGbCtD
Paroxetine—CYP2C8—Phenytoin—epilepsy syndrome	0.00566	0.0271	CbGbCtD
Paroxetine—CYP2C8—Propofol—epilepsy syndrome	0.00528	0.0253	CbGbCtD
Paroxetine—ABCB1—Clobazam—epilepsy syndrome	0.00516	0.0247	CbGbCtD
Paroxetine—CYP2C8—Phenobarbital—epilepsy syndrome	0.00505	0.0241	CbGbCtD
Paroxetine—CYP2B6—Valproic Acid—epilepsy syndrome	0.00498	0.0238	CbGbCtD
Paroxetine—ABCB1—Lamotrigine—epilepsy syndrome	0.00497	0.0238	CbGbCtD
Paroxetine—CYP2C8—Diazepam—epilepsy syndrome	0.00479	0.0229	CbGbCtD
Paroxetine—CYP2C9—Carbamazepine—epilepsy syndrome	0.0044	0.0211	CbGbCtD
Paroxetine—ABCB1—Carbamazepine—epilepsy syndrome	0.00427	0.0204	CbGbCtD
Paroxetine—CYP2C9—Primidone—epilepsy syndrome	0.00411	0.0197	CbGbCtD
Paroxetine—CYP2C9—Phenytoin—epilepsy syndrome	0.00395	0.0189	CbGbCtD
Paroxetine—ABCB1—Phenytoin—epilepsy syndrome	0.00383	0.0183	CbGbCtD
Paroxetine—CYP2C8—Valproic Acid—epilepsy syndrome	0.00377	0.018	CbGbCtD
Paroxetine—CYP2C9—Propofol—epilepsy syndrome	0.00368	0.0176	CbGbCtD
Paroxetine—CYP2C9—Phenobarbital—epilepsy syndrome	0.00352	0.0168	CbGbCtD
Paroxetine—ABCB1—Phenobarbital—epilepsy syndrome	0.00342	0.0163	CbGbCtD
Paroxetine—ABCB1—Midazolam—epilepsy syndrome	0.00337	0.0161	CbGbCtD
Paroxetine—CYP2D6—Propofol—epilepsy syndrome	0.00337	0.0161	CbGbCtD
Paroxetine—CYP2C9—Diazepam—epilepsy syndrome	0.00334	0.016	CbGbCtD
Paroxetine—ABCB1—Diazepam—epilepsy syndrome	0.00324	0.0155	CbGbCtD
Paroxetine—TACR1—vagus nerve—epilepsy syndrome	0.00292	0.0987	CbGeAlD
Paroxetine—CYP2C9—Valproic Acid—epilepsy syndrome	0.00263	0.0126	CbGbCtD
Paroxetine—HTR2A—phrenic nerve—epilepsy syndrome	0.00208	0.0704	CbGeAlD
Paroxetine—SLC6A2—locus ceruleus—epilepsy syndrome	0.00155	0.0523	CbGeAlD
Paroxetine—TACR1—ganglion—epilepsy syndrome	0.00113	0.0381	CbGeAlD
Paroxetine—HTR2A—locus ceruleus—epilepsy syndrome	0.00093	0.0314	CbGeAlD
Paroxetine—SLC6A3—telencephalic ventricle—epilepsy syndrome	0.00091	0.0308	CbGeAlD
Paroxetine—SLC6A2—autonomic nervous system—epilepsy syndrome	0.000822	0.0278	CbGeAlD
Paroxetine—HTR2A—cerebellar cortex—epilepsy syndrome	0.000758	0.0256	CbGeAlD
Paroxetine—HTR2A—vagus nerve—epilepsy syndrome	0.000712	0.0241	CbGeAlD
Paroxetine—SLC6A3—ganglion—epilepsy syndrome	0.000566	0.0191	CbGeAlD
Paroxetine—HTR2A—pons—epilepsy syndrome	0.000536	0.0181	CbGeAlD
Paroxetine—SLC6A4—ganglion—epilepsy syndrome	0.000519	0.0175	CbGeAlD
Paroxetine—HTR2A—autonomic nervous system—epilepsy syndrome	0.000494	0.0167	CbGeAlD
Paroxetine—TACR1—brainstem—epilepsy syndrome	0.000489	0.0165	CbGeAlD
Paroxetine—TACR1—forebrain—epilepsy syndrome	0.000472	0.016	CbGeAlD
Paroxetine—SLC6A2—ganglion—epilepsy syndrome	0.000457	0.0154	CbGeAlD
Paroxetine—HTR2A—telencephalic ventricle—epilepsy syndrome	0.000441	0.0149	CbGeAlD
Paroxetine—TACR1—telencephalon—epilepsy syndrome	0.000434	0.0147	CbGeAlD
Paroxetine—SLC6A3—hindbrain—epilepsy syndrome	0.000429	0.0145	CbGeAlD
Paroxetine—SLC6A4—hindbrain—epilepsy syndrome	0.000393	0.0133	CbGeAlD
Paroxetine—TACR1—spinal cord—epilepsy syndrome	0.000304	0.0103	CbGeAlD
Paroxetine—HTR2A—ganglion—epilepsy syndrome	0.000275	0.00928	CbGeAlD
Paroxetine—TACR1—head—epilepsy syndrome	0.00027	0.00914	CbGeAlD
Paroxetine—TACR1—nervous system—epilepsy syndrome	0.000256	0.00867	CbGeAlD
Paroxetine—CHRM4—head—epilepsy syndrome	0.000254	0.0086	CbGeAlD
Paroxetine—TACR1—central nervous system—epilepsy syndrome	0.000247	0.00835	CbGeAlD
Paroxetine—SLC6A3—brainstem—epilepsy syndrome	0.000246	0.00832	CbGeAlD
Paroxetine—CHRM4—nervous system—epilepsy syndrome	0.000241	0.00815	CbGeAlD
Paroxetine—CHRM2—forebrain—epilepsy syndrome	0.000238	0.00805	CbGeAlD
Paroxetine—SLC6A3—forebrain—epilepsy syndrome	0.000238	0.00803	CbGeAlD
Paroxetine—CHRM4—central nervous system—epilepsy syndrome	0.000232	0.00785	CbGeAlD
Paroxetine—SLC6A4—brainstem—epilepsy syndrome	0.000226	0.00763	CbGeAlD
Paroxetine—CHRM2—telencephalon—epilepsy syndrome	0.000219	0.00741	CbGeAlD
Paroxetine—SLC6A3—telencephalon—epilepsy syndrome	0.000218	0.00739	CbGeAlD
Paroxetine—SLC6A4—forebrain—epilepsy syndrome	0.000218	0.00736	CbGeAlD
Paroxetine—CHRM1—forebrain—epilepsy syndrome	0.000217	0.00733	CbGeAlD
Paroxetine—HTR2A—hindbrain—epilepsy syndrome	0.000208	0.00704	CbGeAlD
Paroxetine—SLC6A4—telencephalon—epilepsy syndrome	0.0002	0.00677	CbGeAlD
Paroxetine—CHRM1—telencephalon—epilepsy syndrome	0.000199	0.00674	CbGeAlD
Paroxetine—CHRM5—head—epilepsy syndrome	0.000199	0.00672	CbGeAlD
Paroxetine—SLC6A2—brainstem—epilepsy syndrome	0.000199	0.00671	CbGeAlD
Paroxetine—TACR1—brain—epilepsy syndrome	0.000196	0.00663	CbGeAlD
Paroxetine—CHRM3—forebrain—epilepsy syndrome	0.000194	0.00656	CbGeAlD
Paroxetine—SLC6A2—forebrain—epilepsy syndrome	0.000192	0.00648	CbGeAlD
Paroxetine—CYP2D6—hindbrain—epilepsy syndrome	0.00019	0.00641	CbGeAlD
Paroxetine—CHRM5—nervous system—epilepsy syndrome	0.000188	0.00637	CbGeAlD
Paroxetine—CHRM4—brain—epilepsy syndrome	0.000184	0.00623	CbGeAlD
Paroxetine—CHRM5—central nervous system—epilepsy syndrome	0.000181	0.00613	CbGeAlD
Paroxetine—CHRM3—telencephalon—epilepsy syndrome	0.000178	0.00603	CbGeAlD
Paroxetine—SLC6A2—telencephalon—epilepsy syndrome	0.000176	0.00596	CbGeAlD
Paroxetine—SLC6A3—midbrain—epilepsy syndrome	0.000157	0.0053	CbGeAlD
Paroxetine—SLC6A3—spinal cord—epilepsy syndrome	0.000153	0.00517	CbGeAlD
Paroxetine—CHRM5—brain—epilepsy syndrome	0.000144	0.00487	CbGeAlD
Paroxetine—SLC6A4—midbrain—epilepsy syndrome	0.000144	0.00486	CbGeAlD
Paroxetine—SLC6A4—spinal cord—epilepsy syndrome	0.00014	0.00474	CbGeAlD
Paroxetine—SLC6A2—medulla oblongata—epilepsy syndrome	0.000138	0.00468	CbGeAlD
Paroxetine—CHRM2—head—epilepsy syndrome	0.000136	0.00461	CbGeAlD
Paroxetine—SLC6A3—head—epilepsy syndrome	0.000136	0.0046	CbGeAlD
Paroxetine—CHRM2—nervous system—epilepsy syndrome	0.000129	0.00437	CbGeAlD
Paroxetine—SLC6A3—nervous system—epilepsy syndrome	0.000129	0.00436	CbGeAlD
Paroxetine—SLC6A4—head—epilepsy syndrome	0.000125	0.00421	CbGeAlD
Paroxetine—CHRM2—central nervous system—epilepsy syndrome	0.000124	0.00421	CbGeAlD
Paroxetine—CHRM1—head—epilepsy syndrome	0.000124	0.0042	CbGeAlD
Paroxetine—SLC6A3—central nervous system—epilepsy syndrome	0.000124	0.0042	CbGeAlD
Paroxetine—SLC6A3—cerebellum—epilepsy syndrome	0.000121	0.0041	CbGeAlD
Paroxetine—HTR2A—brainstem—epilepsy syndrome	0.000119	0.00404	CbGeAlD
Paroxetine—SLC6A4—nervous system—epilepsy syndrome	0.000118	0.004	CbGeAlD
Paroxetine—CHRM1—nervous system—epilepsy syndrome	0.000118	0.00398	CbGeAlD
Paroxetine—HTR2A—forebrain—epilepsy syndrome	0.000115	0.00389	CbGeAlD
Paroxetine—SLC6A4—central nervous system—epilepsy syndrome	0.000114	0.00385	CbGeAlD
Paroxetine—CHRM1—central nervous system—epilepsy syndrome	0.000113	0.00383	CbGeAlD
Paroxetine—CHRM3—head—epilepsy syndrome	0.000111	0.00376	CbGeAlD
Paroxetine—SLC6A2—head—epilepsy syndrome	0.00011	0.00371	CbGeAlD
Paroxetine—CYP2D6—brainstem—epilepsy syndrome	0.000109	0.00368	CbGeAlD
Paroxetine—HTR2A—telencephalon—epilepsy syndrome	0.000106	0.00358	CbGeAlD
Paroxetine—CHRM3—nervous system—epilepsy syndrome	0.000105	0.00356	CbGeAlD
Paroxetine—CYP2D6—forebrain—epilepsy syndrome	0.000105	0.00355	CbGeAlD
Paroxetine—SLC6A2—nervous system—epilepsy syndrome	0.000104	0.00352	CbGeAlD
Paroxetine—CHRM3—central nervous system—epilepsy syndrome	0.000101	0.00343	CbGeAlD
Paroxetine—SLC6A2—central nervous system—epilepsy syndrome	0.0001	0.00339	CbGeAlD
Paroxetine—CHRM2—brain—epilepsy syndrome	9.88e-05	0.00334	CbGeAlD
Paroxetine—SLC6A3—brain—epilepsy syndrome	9.86e-05	0.00333	CbGeAlD
Paroxetine—CYP2D6—telencephalon—epilepsy syndrome	9.65e-05	0.00326	CbGeAlD
Paroxetine—SLC6A4—brain—epilepsy syndrome	9.03e-05	0.00305	CbGeAlD
Paroxetine—CHRM1—brain—epilepsy syndrome	9e-05	0.00304	CbGeAlD
Paroxetine—HTR2A—medulla oblongata—epilepsy syndrome	8.32e-05	0.00281	CbGeAlD
Paroxetine—CYP2B6—head—epilepsy syndrome	8.08e-05	0.00273	CbGeAlD
Paroxetine—CHRM3—brain—epilepsy syndrome	8.05e-05	0.00272	CbGeAlD
Paroxetine—SLC6A2—brain—epilepsy syndrome	7.95e-05	0.00269	CbGeAlD
Paroxetine—CYP2B6—nervous system—epilepsy syndrome	7.66e-05	0.00259	CbGeAlD
Paroxetine—HTR2A—midbrain—epilepsy syndrome	7.61e-05	0.00257	CbGeAlD
Paroxetine—ABCB1—forebrain—epilepsy syndrome	7.55e-05	0.00255	CbGeAlD
Paroxetine—HTR2A—spinal cord—epilepsy syndrome	7.42e-05	0.00251	CbGeAlD
Paroxetine—CYP2B6—central nervous system—epilepsy syndrome	7.38e-05	0.0025	CbGeAlD
Paroxetine—ABCB1—telencephalon—epilepsy syndrome	6.94e-05	0.00235	CbGeAlD
Paroxetine—HTR2A—head—epilepsy syndrome	6.59e-05	0.00223	CbGeAlD
Paroxetine—CYP2C8—brain—epilepsy syndrome	6.53e-05	0.00221	CbGeAlD
Paroxetine—HTR2A—nervous system—epilepsy syndrome	6.25e-05	0.00211	CbGeAlD
Paroxetine—HTR2A—central nervous system—epilepsy syndrome	6.02e-05	0.00204	CbGeAlD
Paroxetine—CYP2D6—head—epilepsy syndrome	6.01e-05	0.00203	CbGeAlD
Paroxetine—HTR2A—cerebellum—epilepsy syndrome	5.88e-05	0.00199	CbGeAlD
Paroxetine—CYP2B6—brain—epilepsy syndrome	5.86e-05	0.00198	CbGeAlD
Paroxetine—CYP2D6—nervous system—epilepsy syndrome	5.7e-05	0.00193	CbGeAlD
Paroxetine—CYP2D6—central nervous system—epilepsy syndrome	5.48e-05	0.00185	CbGeAlD
Paroxetine—ABCB1—medulla oblongata—epilepsy syndrome	5.45e-05	0.00184	CbGeAlD
Paroxetine—CYP2D6—cerebellum—epilepsy syndrome	5.36e-05	0.00181	CbGeAlD
Paroxetine—ABCB1—midbrain—epilepsy syndrome	4.98e-05	0.00169	CbGeAlD
Paroxetine—ABCB1—spinal cord—epilepsy syndrome	4.86e-05	0.00164	CbGeAlD
Paroxetine—HTR2A—brain—epilepsy syndrome	4.78e-05	0.00162	CbGeAlD
Paroxetine—CYP2D6—brain—epilepsy syndrome	4.35e-05	0.00147	CbGeAlD
Paroxetine—ABCB1—head—epilepsy syndrome	4.32e-05	0.00146	CbGeAlD
Paroxetine—ABCB1—nervous system—epilepsy syndrome	4.1e-05	0.00139	CbGeAlD
Paroxetine—ABCB1—central nervous system—epilepsy syndrome	3.94e-05	0.00133	CbGeAlD
Paroxetine—ABCB1—cerebellum—epilepsy syndrome	3.86e-05	0.0013	CbGeAlD
Paroxetine—ABCB1—brain—epilepsy syndrome	3.13e-05	0.00106	CbGeAlD
Paroxetine—Anaemia—Gabapentin—epilepsy syndrome	7.73e-06	6.22e-05	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	7.71e-06	6.21e-05	CcSEcCtD
Paroxetine—Hypotension—Valproic Acid—epilepsy syndrome	7.69e-06	6.19e-05	CcSEcCtD
Paroxetine—Asthenia—Carbamazepine—epilepsy syndrome	7.69e-06	6.19e-05	CcSEcCtD
Paroxetine—Agitation—Gabapentin—epilepsy syndrome	7.69e-06	6.19e-05	CcSEcCtD
Paroxetine—Diarrhoea—Phenytoin—epilepsy syndrome	7.68e-06	6.19e-05	CcSEcCtD
Paroxetine—Discomfort—Pregabalin—epilepsy syndrome	7.67e-06	6.18e-05	CcSEcCtD
Paroxetine—Nausea—Fosphenytoin—epilepsy syndrome	7.67e-06	6.17e-05	CcSEcCtD
Paroxetine—Diarrhoea—Oxcarbazepine—epilepsy syndrome	7.64e-06	6.15e-05	CcSEcCtD
Paroxetine—Erythema multiforme—Topiramate—epilepsy syndrome	7.64e-06	6.15e-05	CcSEcCtD
Paroxetine—Angioedema—Gabapentin—epilepsy syndrome	7.64e-06	6.15e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Lamotrigine—epilepsy syndrome	7.63e-06	6.15e-05	CcSEcCtD
Paroxetine—Vomiting—Felbamate—epilepsy syndrome	7.62e-06	6.13e-05	CcSEcCtD
Paroxetine—Dry mouth—Pregabalin—epilepsy syndrome	7.59e-06	6.11e-05	CcSEcCtD
Paroxetine—Pruritus—Carbamazepine—epilepsy syndrome	7.59e-06	6.11e-05	CcSEcCtD
Paroxetine—Rash—Felbamate—epilepsy syndrome	7.56e-06	6.08e-05	CcSEcCtD
Paroxetine—Eye disorder—Topiramate—epilepsy syndrome	7.55e-06	6.08e-05	CcSEcCtD
Paroxetine—Dermatitis—Felbamate—epilepsy syndrome	7.55e-06	6.08e-05	CcSEcCtD
Paroxetine—Malaise—Gabapentin—epilepsy syndrome	7.54e-06	6.07e-05	CcSEcCtD
Paroxetine—Tinnitus—Topiramate—epilepsy syndrome	7.54e-06	6.07e-05	CcSEcCtD
Paroxetine—Vertigo—Gabapentin—epilepsy syndrome	7.51e-06	6.05e-05	CcSEcCtD
Paroxetine—Headache—Felbamate—epilepsy syndrome	7.51e-06	6.04e-05	CcSEcCtD
Paroxetine—Confusional state—Pregabalin—epilepsy syndrome	7.51e-06	6.04e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	7.5e-06	6.04e-05	CcSEcCtD
Paroxetine—Cardiac disorder—Topiramate—epilepsy syndrome	7.5e-06	6.04e-05	CcSEcCtD
Paroxetine—Flushing—Topiramate—epilepsy syndrome	7.5e-06	6.04e-05	CcSEcCtD
Paroxetine—Syncope—Gabapentin—epilepsy syndrome	7.5e-06	6.04e-05	CcSEcCtD
Paroxetine—Leukopenia—Gabapentin—epilepsy syndrome	7.49e-06	6.03e-05	CcSEcCtD
Paroxetine—Dizziness—Clonazepam—epilepsy syndrome	7.48e-06	6.02e-05	CcSEcCtD
Paroxetine—Nausea—Vigabatrin—epilepsy syndrome	7.47e-06	6.01e-05	CcSEcCtD
Paroxetine—Vomiting—Zonisamide—epilepsy syndrome	7.46e-06	6.01e-05	CcSEcCtD
Paroxetine—Insomnia—Valproic Acid—epilepsy syndrome	7.45e-06	5.99e-05	CcSEcCtD
Paroxetine—Anaphylactic shock—Pregabalin—epilepsy syndrome	7.44e-06	5.99e-05	CcSEcCtD
Paroxetine—Oedema—Pregabalin—epilepsy syndrome	7.44e-06	5.99e-05	CcSEcCtD
Paroxetine—Asthenia—Lamotrigine—epilepsy syndrome	7.43e-06	5.98e-05	CcSEcCtD
Paroxetine—Dizziness—Phenytoin—epilepsy syndrome	7.43e-06	5.98e-05	CcSEcCtD
Paroxetine—Rash—Zonisamide—epilepsy syndrome	7.4e-06	5.96e-05	CcSEcCtD
Paroxetine—Infection—Pregabalin—epilepsy syndrome	7.4e-06	5.95e-05	CcSEcCtD
Paroxetine—Paraesthesia—Valproic Acid—epilepsy syndrome	7.39e-06	5.95e-05	CcSEcCtD
Paroxetine—Palpitations—Gabapentin—epilepsy syndrome	7.39e-06	5.95e-05	CcSEcCtD
Paroxetine—Dermatitis—Zonisamide—epilepsy syndrome	7.39e-06	5.95e-05	CcSEcCtD
Paroxetine—Dizziness—Oxcarbazepine—epilepsy syndrome	7.39e-06	5.95e-05	CcSEcCtD
Paroxetine—Nausea—Diazepam—epilepsy syndrome	7.36e-06	5.92e-05	CcSEcCtD
Paroxetine—Loss of consciousness—Gabapentin—epilepsy syndrome	7.35e-06	5.92e-05	CcSEcCtD
Paroxetine—Headache—Zonisamide—epilepsy syndrome	7.35e-06	5.92e-05	CcSEcCtD
Paroxetine—Dyspnoea—Valproic Acid—epilepsy syndrome	7.34e-06	5.91e-05	CcSEcCtD
Paroxetine—Diarrhoea—Carbamazepine—epilepsy syndrome	7.34e-06	5.91e-05	CcSEcCtD
Paroxetine—Angiopathy—Topiramate—epilepsy syndrome	7.33e-06	5.9e-05	CcSEcCtD
Paroxetine—Pruritus—Lamotrigine—epilepsy syndrome	7.33e-06	5.9e-05	CcSEcCtD
Paroxetine—Shock—Pregabalin—epilepsy syndrome	7.32e-06	5.9e-05	CcSEcCtD
Paroxetine—Somnolence—Valproic Acid—epilepsy syndrome	7.32e-06	5.89e-05	CcSEcCtD
Paroxetine—Immune system disorder—Topiramate—epilepsy syndrome	7.3e-06	5.88e-05	CcSEcCtD
Paroxetine—Nervous system disorder—Pregabalin—epilepsy syndrome	7.3e-06	5.88e-05	CcSEcCtD
Paroxetine—Cough—Gabapentin—epilepsy syndrome	7.3e-06	5.88e-05	CcSEcCtD
Paroxetine—Thrombocytopenia—Pregabalin—epilepsy syndrome	7.29e-06	5.87e-05	CcSEcCtD
Paroxetine—Mediastinal disorder—Topiramate—epilepsy syndrome	7.28e-06	5.86e-05	CcSEcCtD
Paroxetine—Tachycardia—Pregabalin—epilepsy syndrome	7.26e-06	5.85e-05	CcSEcCtD
Paroxetine—Chills—Topiramate—epilepsy syndrome	7.25e-06	5.84e-05	CcSEcCtD
Paroxetine—Dyspepsia—Valproic Acid—epilepsy syndrome	7.25e-06	5.83e-05	CcSEcCtD
Paroxetine—Convulsion—Gabapentin—epilepsy syndrome	7.25e-06	5.83e-05	CcSEcCtD
Paroxetine—Skin disorder—Pregabalin—epilepsy syndrome	7.23e-06	5.82e-05	CcSEcCtD
Paroxetine—Hypertension—Gabapentin—epilepsy syndrome	7.22e-06	5.81e-05	CcSEcCtD
Paroxetine—Hyperhidrosis—Pregabalin—epilepsy syndrome	7.2e-06	5.79e-05	CcSEcCtD
Paroxetine—Vomiting—Clonazepam—epilepsy syndrome	7.19e-06	5.79e-05	CcSEcCtD
Paroxetine—Decreased appetite—Valproic Acid—epilepsy syndrome	7.16e-06	5.76e-05	CcSEcCtD
Paroxetine—Alopecia—Topiramate—epilepsy syndrome	7.14e-06	5.75e-05	CcSEcCtD
Paroxetine—Vomiting—Phenytoin—epilepsy syndrome	7.14e-06	5.75e-05	CcSEcCtD
Paroxetine—Rash—Clonazepam—epilepsy syndrome	7.13e-06	5.74e-05	CcSEcCtD
Paroxetine—Dermatitis—Clonazepam—epilepsy syndrome	7.12e-06	5.73e-05	CcSEcCtD
Paroxetine—Arthralgia—Gabapentin—epilepsy syndrome	7.12e-06	5.73e-05	CcSEcCtD
Paroxetine—Myalgia—Gabapentin—epilepsy syndrome	7.12e-06	5.73e-05	CcSEcCtD
Paroxetine—Chest pain—Gabapentin—epilepsy syndrome	7.12e-06	5.73e-05	CcSEcCtD
Paroxetine—Nausea—Felbamate—epilepsy syndrome	7.12e-06	5.73e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	7.11e-06	5.72e-05	CcSEcCtD
Paroxetine—Vomiting—Oxcarbazepine—epilepsy syndrome	7.1e-06	5.72e-05	CcSEcCtD
Paroxetine—Fatigue—Valproic Acid—epilepsy syndrome	7.1e-06	5.71e-05	CcSEcCtD
Paroxetine—Anxiety—Gabapentin—epilepsy syndrome	7.1e-06	5.71e-05	CcSEcCtD
Paroxetine—Dizziness—Carbamazepine—epilepsy syndrome	7.09e-06	5.71e-05	CcSEcCtD
Paroxetine—Diarrhoea—Lamotrigine—epilepsy syndrome	7.09e-06	5.71e-05	CcSEcCtD
Paroxetine—Headache—Clonazepam—epilepsy syndrome	7.08e-06	5.7e-05	CcSEcCtD
Paroxetine—Rash—Phenytoin—epilepsy syndrome	7.08e-06	5.7e-05	CcSEcCtD
Paroxetine—Mental disorder—Topiramate—epilepsy syndrome	7.08e-06	5.7e-05	CcSEcCtD
Paroxetine—Dermatitis—Phenytoin—epilepsy syndrome	7.08e-06	5.7e-05	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	7.07e-06	5.69e-05	CcSEcCtD
Paroxetine—Rash—Oxcarbazepine—epilepsy syndrome	7.04e-06	5.67e-05	CcSEcCtD
Paroxetine—Pain—Valproic Acid—epilepsy syndrome	7.04e-06	5.67e-05	CcSEcCtD
Paroxetine—Constipation—Valproic Acid—epilepsy syndrome	7.04e-06	5.67e-05	CcSEcCtD
Paroxetine—Dermatitis—Oxcarbazepine—epilepsy syndrome	7.04e-06	5.67e-05	CcSEcCtD
Paroxetine—Headache—Phenytoin—epilepsy syndrome	7.04e-06	5.66e-05	CcSEcCtD
Paroxetine—Erythema—Topiramate—epilepsy syndrome	7.04e-06	5.66e-05	CcSEcCtD
Paroxetine—Malnutrition—Topiramate—epilepsy syndrome	7.04e-06	5.66e-05	CcSEcCtD
Paroxetine—Discomfort—Gabapentin—epilepsy syndrome	7.03e-06	5.66e-05	CcSEcCtD
Paroxetine—Headache—Oxcarbazepine—epilepsy syndrome	7e-06	5.63e-05	CcSEcCtD
Paroxetine—Nausea—Zonisamide—epilepsy syndrome	6.97e-06	5.61e-05	CcSEcCtD
Paroxetine—Dry mouth—Gabapentin—epilepsy syndrome	6.96e-06	5.61e-05	CcSEcCtD
Paroxetine—Hypotension—Pregabalin—epilepsy syndrome	6.96e-06	5.6e-05	CcSEcCtD
Paroxetine—Flatulence—Topiramate—epilepsy syndrome	6.93e-06	5.58e-05	CcSEcCtD
Paroxetine—Tension—Topiramate—epilepsy syndrome	6.9e-06	5.56e-05	CcSEcCtD
Paroxetine—Dysgeusia—Topiramate—epilepsy syndrome	6.89e-06	5.55e-05	CcSEcCtD
Paroxetine—Confusional state—Gabapentin—epilepsy syndrome	6.88e-06	5.54e-05	CcSEcCtD
Paroxetine—Dizziness—Lamotrigine—epilepsy syndrome	6.85e-06	5.52e-05	CcSEcCtD
Paroxetine—Nervousness—Topiramate—epilepsy syndrome	6.83e-06	5.5e-05	CcSEcCtD
Paroxetine—Anaphylactic shock—Gabapentin—epilepsy syndrome	6.83e-06	5.49e-05	CcSEcCtD
Paroxetine—Oedema—Gabapentin—epilepsy syndrome	6.83e-06	5.49e-05	CcSEcCtD
Paroxetine—Vomiting—Carbamazepine—epilepsy syndrome	6.82e-06	5.49e-05	CcSEcCtD
Paroxetine—Back pain—Topiramate—epilepsy syndrome	6.81e-06	5.48e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Valproic Acid—epilepsy syndrome	6.79e-06	5.46e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	6.78e-06	5.46e-05	CcSEcCtD
Paroxetine—Infection—Gabapentin—epilepsy syndrome	6.78e-06	5.46e-05	CcSEcCtD
Paroxetine—Muscle spasms—Topiramate—epilepsy syndrome	6.76e-06	5.45e-05	CcSEcCtD
Paroxetine—Rash—Carbamazepine—epilepsy syndrome	6.76e-06	5.44e-05	CcSEcCtD
Paroxetine—Dermatitis—Carbamazepine—epilepsy syndrome	6.75e-06	5.44e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	6.73e-06	5.42e-05	CcSEcCtD
Paroxetine—Insomnia—Pregabalin—epilepsy syndrome	6.73e-06	5.42e-05	CcSEcCtD
Paroxetine—Nausea—Clonazepam—epilepsy syndrome	6.72e-06	5.41e-05	CcSEcCtD
Paroxetine—Headache—Carbamazepine—epilepsy syndrome	6.72e-06	5.41e-05	CcSEcCtD
Paroxetine—Shock—Gabapentin—epilepsy syndrome	6.72e-06	5.41e-05	CcSEcCtD
Paroxetine—Nervous system disorder—Gabapentin—epilepsy syndrome	6.69e-06	5.39e-05	CcSEcCtD
Paroxetine—Paraesthesia—Pregabalin—epilepsy syndrome	6.68e-06	5.38e-05	CcSEcCtD
Paroxetine—Thrombocytopenia—Gabapentin—epilepsy syndrome	6.68e-06	5.38e-05	CcSEcCtD
Paroxetine—Nausea—Phenytoin—epilepsy syndrome	6.67e-06	5.37e-05	CcSEcCtD
Paroxetine—Tachycardia—Gabapentin—epilepsy syndrome	6.66e-06	5.36e-05	CcSEcCtD
Paroxetine—Dyspnoea—Pregabalin—epilepsy syndrome	6.64e-06	5.34e-05	CcSEcCtD
Paroxetine—Nausea—Oxcarbazepine—epilepsy syndrome	6.64e-06	5.34e-05	CcSEcCtD
Paroxetine—Vision blurred—Topiramate—epilepsy syndrome	6.63e-06	5.34e-05	CcSEcCtD
Paroxetine—Skin disorder—Gabapentin—epilepsy syndrome	6.63e-06	5.34e-05	CcSEcCtD
Paroxetine—Somnolence—Pregabalin—epilepsy syndrome	6.62e-06	5.33e-05	CcSEcCtD
Paroxetine—Hyperhidrosis—Gabapentin—epilepsy syndrome	6.6e-06	5.31e-05	CcSEcCtD
Paroxetine—Tremor—Topiramate—epilepsy syndrome	6.59e-06	5.31e-05	CcSEcCtD
Paroxetine—Vomiting—Lamotrigine—epilepsy syndrome	6.59e-06	5.3e-05	CcSEcCtD
Paroxetine—Urticaria—Valproic Acid—epilepsy syndrome	6.54e-06	5.27e-05	CcSEcCtD
Paroxetine—Rash—Lamotrigine—epilepsy syndrome	6.53e-06	5.26e-05	CcSEcCtD
Paroxetine—Ill-defined disorder—Topiramate—epilepsy syndrome	6.53e-06	5.26e-05	CcSEcCtD
Paroxetine—Dermatitis—Lamotrigine—epilepsy syndrome	6.53e-06	5.25e-05	CcSEcCtD
Paroxetine—Body temperature increased—Valproic Acid—epilepsy syndrome	6.51e-06	5.24e-05	CcSEcCtD
Paroxetine—Abdominal pain—Valproic Acid—epilepsy syndrome	6.51e-06	5.24e-05	CcSEcCtD
Paroxetine—Anaemia—Topiramate—epilepsy syndrome	6.5e-06	5.24e-05	CcSEcCtD
Paroxetine—Headache—Lamotrigine—epilepsy syndrome	6.49e-06	5.23e-05	CcSEcCtD
Paroxetine—Decreased appetite—Pregabalin—epilepsy syndrome	6.47e-06	5.21e-05	CcSEcCtD
Paroxetine—Agitation—Topiramate—epilepsy syndrome	6.47e-06	5.21e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	6.43e-06	5.17e-05	CcSEcCtD
Paroxetine—Fatigue—Pregabalin—epilepsy syndrome	6.42e-06	5.17e-05	CcSEcCtD
Paroxetine—Hypotension—Gabapentin—epilepsy syndrome	6.38e-06	5.13e-05	CcSEcCtD
Paroxetine—Nausea—Carbamazepine—epilepsy syndrome	6.37e-06	5.13e-05	CcSEcCtD
Paroxetine—Pain—Pregabalin—epilepsy syndrome	6.37e-06	5.12e-05	CcSEcCtD
Paroxetine—Constipation—Pregabalin—epilepsy syndrome	6.37e-06	5.12e-05	CcSEcCtD
Paroxetine—Malaise—Topiramate—epilepsy syndrome	6.35e-06	5.11e-05	CcSEcCtD
Paroxetine—Vertigo—Topiramate—epilepsy syndrome	6.32e-06	5.09e-05	CcSEcCtD
Paroxetine—Syncope—Topiramate—epilepsy syndrome	6.31e-06	5.08e-05	CcSEcCtD
Paroxetine—Leukopenia—Topiramate—epilepsy syndrome	6.3e-06	5.07e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	6.22e-06	5.01e-05	CcSEcCtD
Paroxetine—Palpitations—Topiramate—epilepsy syndrome	6.22e-06	5.01e-05	CcSEcCtD
Paroxetine—Loss of consciousness—Topiramate—epilepsy syndrome	6.18e-06	4.98e-05	CcSEcCtD
Paroxetine—Insomnia—Gabapentin—epilepsy syndrome	6.17e-06	4.97e-05	CcSEcCtD
Paroxetine—Nausea—Lamotrigine—epilepsy syndrome	6.15e-06	4.95e-05	CcSEcCtD
Paroxetine—Cough—Topiramate—epilepsy syndrome	6.14e-06	4.94e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Pregabalin—epilepsy syndrome	6.13e-06	4.94e-05	CcSEcCtD
Paroxetine—Paraesthesia—Gabapentin—epilepsy syndrome	6.13e-06	4.93e-05	CcSEcCtD
Paroxetine—Convulsion—Topiramate—epilepsy syndrome	6.1e-06	4.91e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Pregabalin—epilepsy syndrome	6.09e-06	4.9e-05	CcSEcCtD
Paroxetine—Dyspnoea—Gabapentin—epilepsy syndrome	6.09e-06	4.9e-05	CcSEcCtD
Paroxetine—Hypertension—Topiramate—epilepsy syndrome	6.07e-06	4.89e-05	CcSEcCtD
Paroxetine—Somnolence—Gabapentin—epilepsy syndrome	6.07e-06	4.88e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Valproic Acid—epilepsy syndrome	6.07e-06	4.88e-05	CcSEcCtD
Paroxetine—Dyspepsia—Gabapentin—epilepsy syndrome	6.01e-06	4.84e-05	CcSEcCtD
Paroxetine—Arthralgia—Topiramate—epilepsy syndrome	5.99e-06	4.82e-05	CcSEcCtD
Paroxetine—Chest pain—Topiramate—epilepsy syndrome	5.99e-06	4.82e-05	CcSEcCtD
Paroxetine—Myalgia—Topiramate—epilepsy syndrome	5.99e-06	4.82e-05	CcSEcCtD
Paroxetine—Anxiety—Topiramate—epilepsy syndrome	5.97e-06	4.81e-05	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	5.95e-06	4.79e-05	CcSEcCtD
Paroxetine—Decreased appetite—Gabapentin—epilepsy syndrome	5.93e-06	4.78e-05	CcSEcCtD
Paroxetine—Discomfort—Topiramate—epilepsy syndrome	5.92e-06	4.76e-05	CcSEcCtD
Paroxetine—Urticaria—Pregabalin—epilepsy syndrome	5.91e-06	4.76e-05	CcSEcCtD
Paroxetine—Asthenia—Valproic Acid—epilepsy syndrome	5.91e-06	4.76e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	5.89e-06	4.74e-05	CcSEcCtD
Paroxetine—Fatigue—Gabapentin—epilepsy syndrome	5.88e-06	4.74e-05	CcSEcCtD
Paroxetine—Body temperature increased—Pregabalin—epilepsy syndrome	5.88e-06	4.74e-05	CcSEcCtD
Paroxetine—Abdominal pain—Pregabalin—epilepsy syndrome	5.88e-06	4.74e-05	CcSEcCtD
Paroxetine—Dry mouth—Topiramate—epilepsy syndrome	5.86e-06	4.72e-05	CcSEcCtD
Paroxetine—Pain—Gabapentin—epilepsy syndrome	5.84e-06	4.7e-05	CcSEcCtD
Paroxetine—Constipation—Gabapentin—epilepsy syndrome	5.84e-06	4.7e-05	CcSEcCtD
Paroxetine—Pruritus—Valproic Acid—epilepsy syndrome	5.83e-06	4.69e-05	CcSEcCtD
Paroxetine—Confusional state—Topiramate—epilepsy syndrome	5.79e-06	4.66e-05	CcSEcCtD
Paroxetine—Oedema—Topiramate—epilepsy syndrome	5.74e-06	4.62e-05	CcSEcCtD
Paroxetine—Infection—Topiramate—epilepsy syndrome	5.71e-06	4.59e-05	CcSEcCtD
Paroxetine—Shock—Topiramate—epilepsy syndrome	5.65e-06	4.55e-05	CcSEcCtD
Paroxetine—Diarrhoea—Valproic Acid—epilepsy syndrome	5.63e-06	4.54e-05	CcSEcCtD
Paroxetine—Nervous system disorder—Topiramate—epilepsy syndrome	5.63e-06	4.53e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Gabapentin—epilepsy syndrome	5.62e-06	4.53e-05	CcSEcCtD
Paroxetine—Thrombocytopenia—Topiramate—epilepsy syndrome	5.62e-06	4.53e-05	CcSEcCtD
Paroxetine—Tachycardia—Topiramate—epilepsy syndrome	5.6e-06	4.51e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Gabapentin—epilepsy syndrome	5.58e-06	4.49e-05	CcSEcCtD
Paroxetine—Skin disorder—Topiramate—epilepsy syndrome	5.58e-06	4.49e-05	CcSEcCtD
Paroxetine—Hyperhidrosis—Topiramate—epilepsy syndrome	5.55e-06	4.47e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Pregabalin—epilepsy syndrome	5.48e-06	4.41e-05	CcSEcCtD
Paroxetine—Dizziness—Valproic Acid—epilepsy syndrome	5.44e-06	4.38e-05	CcSEcCtD
Paroxetine—Urticaria—Gabapentin—epilepsy syndrome	5.42e-06	4.37e-05	CcSEcCtD
Paroxetine—Body temperature increased—Gabapentin—epilepsy syndrome	5.4e-06	4.34e-05	CcSEcCtD
Paroxetine—Abdominal pain—Gabapentin—epilepsy syndrome	5.4e-06	4.34e-05	CcSEcCtD
Paroxetine—Hypotension—Topiramate—epilepsy syndrome	5.37e-06	4.32e-05	CcSEcCtD
Paroxetine—Asthenia—Pregabalin—epilepsy syndrome	5.34e-06	4.3e-05	CcSEcCtD
Paroxetine—Pruritus—Pregabalin—epilepsy syndrome	5.27e-06	4.24e-05	CcSEcCtD
Paroxetine—Vomiting—Valproic Acid—epilepsy syndrome	5.24e-06	4.21e-05	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	5.23e-06	4.21e-05	CcSEcCtD
Paroxetine—Insomnia—Topiramate—epilepsy syndrome	5.19e-06	4.18e-05	CcSEcCtD
Paroxetine—Rash—Valproic Acid—epilepsy syndrome	5.19e-06	4.18e-05	CcSEcCtD
Paroxetine—Dermatitis—Valproic Acid—epilepsy syndrome	5.19e-06	4.18e-05	CcSEcCtD
Paroxetine—Headache—Valproic Acid—epilepsy syndrome	5.16e-06	4.15e-05	CcSEcCtD
Paroxetine—Paraesthesia—Topiramate—epilepsy syndrome	5.16e-06	4.15e-05	CcSEcCtD
Paroxetine—Dyspnoea—Topiramate—epilepsy syndrome	5.12e-06	4.12e-05	CcSEcCtD
Paroxetine—Somnolence—Topiramate—epilepsy syndrome	5.11e-06	4.11e-05	CcSEcCtD
Paroxetine—Diarrhoea—Pregabalin—epilepsy syndrome	5.09e-06	4.1e-05	CcSEcCtD
Paroxetine—Dyspepsia—Topiramate—epilepsy syndrome	5.05e-06	4.07e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Gabapentin—epilepsy syndrome	5.03e-06	4.05e-05	CcSEcCtD
Paroxetine—Decreased appetite—Topiramate—epilepsy syndrome	4.99e-06	4.02e-05	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Topiramate—epilepsy syndrome	4.96e-06	3.99e-05	CcSEcCtD
Paroxetine—Fatigue—Topiramate—epilepsy syndrome	4.95e-06	3.99e-05	CcSEcCtD
Paroxetine—Dizziness—Pregabalin—epilepsy syndrome	4.92e-06	3.96e-05	CcSEcCtD
Paroxetine—Constipation—Topiramate—epilepsy syndrome	4.91e-06	3.95e-05	CcSEcCtD
Paroxetine—Pain—Topiramate—epilepsy syndrome	4.91e-06	3.95e-05	CcSEcCtD
Paroxetine—Asthenia—Gabapentin—epilepsy syndrome	4.9e-06	3.94e-05	CcSEcCtD
Paroxetine—Nausea—Valproic Acid—epilepsy syndrome	4.89e-06	3.94e-05	CcSEcCtD
Paroxetine—Pruritus—Gabapentin—epilepsy syndrome	4.83e-06	3.89e-05	CcSEcCtD
Paroxetine—Vomiting—Pregabalin—epilepsy syndrome	4.73e-06	3.81e-05	CcSEcCtD
Paroxetine—Feeling abnormal—Topiramate—epilepsy syndrome	4.73e-06	3.81e-05	CcSEcCtD
Paroxetine—Gastrointestinal pain—Topiramate—epilepsy syndrome	4.7e-06	3.78e-05	CcSEcCtD
Paroxetine—Rash—Pregabalin—epilepsy syndrome	4.69e-06	3.78e-05	CcSEcCtD
Paroxetine—Dermatitis—Pregabalin—epilepsy syndrome	4.69e-06	3.77e-05	CcSEcCtD
Paroxetine—Diarrhoea—Gabapentin—epilepsy syndrome	4.67e-06	3.76e-05	CcSEcCtD
Paroxetine—Headache—Pregabalin—epilepsy syndrome	4.66e-06	3.75e-05	CcSEcCtD
Paroxetine—Urticaria—Topiramate—epilepsy syndrome	4.56e-06	3.67e-05	CcSEcCtD
Paroxetine—Abdominal pain—Topiramate—epilepsy syndrome	4.54e-06	3.65e-05	CcSEcCtD
Paroxetine—Body temperature increased—Topiramate—epilepsy syndrome	4.54e-06	3.65e-05	CcSEcCtD
Paroxetine—Dizziness—Gabapentin—epilepsy syndrome	4.51e-06	3.63e-05	CcSEcCtD
Paroxetine—Nausea—Pregabalin—epilepsy syndrome	4.42e-06	3.56e-05	CcSEcCtD
Paroxetine—Vomiting—Gabapentin—epilepsy syndrome	4.34e-06	3.49e-05	CcSEcCtD
Paroxetine—Rash—Gabapentin—epilepsy syndrome	4.3e-06	3.46e-05	CcSEcCtD
Paroxetine—Dermatitis—Gabapentin—epilepsy syndrome	4.3e-06	3.46e-05	CcSEcCtD
Paroxetine—Headache—Gabapentin—epilepsy syndrome	4.28e-06	3.44e-05	CcSEcCtD
Paroxetine—Hypersensitivity—Topiramate—epilepsy syndrome	4.23e-06	3.41e-05	CcSEcCtD
Paroxetine—Asthenia—Topiramate—epilepsy syndrome	4.12e-06	3.32e-05	CcSEcCtD
Paroxetine—Pruritus—Topiramate—epilepsy syndrome	4.06e-06	3.27e-05	CcSEcCtD
Paroxetine—Nausea—Gabapentin—epilepsy syndrome	4.05e-06	3.26e-05	CcSEcCtD
Paroxetine—Diarrhoea—Topiramate—epilepsy syndrome	3.93e-06	3.16e-05	CcSEcCtD
Paroxetine—Dizziness—Topiramate—epilepsy syndrome	3.8e-06	3.06e-05	CcSEcCtD
Paroxetine—Vomiting—Topiramate—epilepsy syndrome	3.65e-06	2.94e-05	CcSEcCtD
Paroxetine—Rash—Topiramate—epilepsy syndrome	3.62e-06	2.91e-05	CcSEcCtD
Paroxetine—Dermatitis—Topiramate—epilepsy syndrome	3.62e-06	2.91e-05	CcSEcCtD
Paroxetine—Headache—Topiramate—epilepsy syndrome	3.6e-06	2.9e-05	CcSEcCtD
Paroxetine—Nausea—Topiramate—epilepsy syndrome	3.41e-06	2.75e-05	CcSEcCtD
Paroxetine—CYP2D6—Metabolism—ABCG2—epilepsy syndrome	1.38e-06	2.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADAM10—epilepsy syndrome	1.38e-06	2.51e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADAM10—epilepsy syndrome	1.38e-06	2.5e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—CCL2—epilepsy syndrome	1.38e-06	2.5e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—APOE—epilepsy syndrome	1.37e-06	2.49e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—CCL2—epilepsy syndrome	1.37e-06	2.49e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCG2—epilepsy syndrome	1.37e-06	2.49e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADAM10—epilepsy syndrome	1.36e-06	2.48e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—CCL2—epilepsy syndrome	1.36e-06	2.47e-05	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.36e-06	2.46e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—PRKCB—epilepsy syndrome	1.35e-06	2.46e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.35e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6ST—epilepsy syndrome	1.35e-06	2.45e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KDR—epilepsy syndrome	1.35e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GPX1—epilepsy syndrome	1.34e-06	2.44e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.34e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP2C19—epilepsy syndrome	1.34e-06	2.43e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	1.33e-06	2.42e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP11A1—epilepsy syndrome	1.33e-06	2.41e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—epilepsy syndrome	1.32e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	1.32e-06	2.39e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—S100B—epilepsy syndrome	1.31e-06	2.39e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TH—epilepsy syndrome	1.31e-06	2.38e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—S100B—epilepsy syndrome	1.31e-06	2.37e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—S100B—epilepsy syndrome	1.3e-06	2.37e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SOCS3—epilepsy syndrome	1.3e-06	2.36e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CDC42—epilepsy syndrome	1.3e-06	2.36e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—PRKCB—epilepsy syndrome	1.3e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SOCS3—epilepsy syndrome	1.29e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—HMOX1—epilepsy syndrome	1.29e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.29e-06	2.35e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CDC42—epilepsy syndrome	1.29e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—S100B—epilepsy syndrome	1.29e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SOCS3—epilepsy syndrome	1.29e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6ST—epilepsy syndrome	1.29e-06	2.34e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CDC42—epilepsy syndrome	1.29e-06	2.34e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.28e-06	2.33e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SOCS3—epilepsy syndrome	1.28e-06	2.32e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CAT—epilepsy syndrome	1.28e-06	2.32e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CDC42—epilepsy syndrome	1.28e-06	2.31e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AVP—epilepsy syndrome	1.26e-06	2.28e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AVP—epilepsy syndrome	1.25e-06	2.27e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AVP—epilepsy syndrome	1.25e-06	2.26e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ABCB1—epilepsy syndrome	1.24e-06	2.25e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AVP—epilepsy syndrome	1.23e-06	2.24e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—POMC—epilepsy syndrome	1.23e-06	2.24e-05	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.22e-06	2.22e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	1.22e-06	2.22e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—BCHE—epilepsy syndrome	1.22e-06	2.21e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CCL2—epilepsy syndrome	1.21e-06	2.19e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—epilepsy syndrome	1.2e-06	2.18e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP2D6—epilepsy syndrome	1.2e-06	2.18e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—HES1—epilepsy syndrome	1.19e-06	2.16e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HES1—epilepsy syndrome	1.18e-06	2.15e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—POMC—epilepsy syndrome	1.18e-06	2.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HES1—epilepsy syndrome	1.18e-06	2.14e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AGT—epilepsy syndrome	1.18e-06	2.14e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HES1—epilepsy syndrome	1.17e-06	2.12e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	1.16e-06	2.11e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FYN—epilepsy syndrome	1.16e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CCL2—epilepsy syndrome	1.15e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GPX1—epilepsy syndrome	1.15e-06	2.1e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—APOE—epilepsy syndrome	1.15e-06	2.09e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—H2AFX—epilepsy syndrome	1.15e-06	2.09e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.15e-06	2.09e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FYN—epilepsy syndrome	1.15e-06	2.09e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MEF2C—epilepsy syndrome	1.15e-06	2.09e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PLCB1—epilepsy syndrome	1.15e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FYN—epilepsy syndrome	1.15e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.15e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—H2AFX—epilepsy syndrome	1.15e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MEF2C—epilepsy syndrome	1.14e-06	2.08e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TH—epilepsy syndrome	1.14e-06	2.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—H2AFX—epilepsy syndrome	1.14e-06	2.07e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ADRA2A—epilepsy syndrome	1.14e-06	2.07e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MEF2C—epilepsy syndrome	1.14e-06	2.07e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—BCHE—epilepsy syndrome	1.14e-06	2.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FYN—epilepsy syndrome	1.14e-06	2.06e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—H2AFX—epilepsy syndrome	1.13e-06	2.05e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MEF2C—epilepsy syndrome	1.13e-06	2.05e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—YWHAZ—epilepsy syndrome	1.11e-06	2.02e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—YWHAZ—epilepsy syndrome	1.11e-06	2.01e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—YWHAZ—epilepsy syndrome	1.1e-06	2e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NGF—epilepsy syndrome	1.1e-06	1.99e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	1.1e-06	1.99e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	1.09e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NGF—epilepsy syndrome	1.09e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—YWHAZ—epilepsy syndrome	1.09e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—FGF2—epilepsy syndrome	1.09e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NGF—epilepsy syndrome	1.09e-06	1.98e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—SLC2A1—epilepsy syndrome	1.08e-06	1.97e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	1.08e-06	1.96e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CAT—epilepsy syndrome	1.08e-06	1.96e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NGF—epilepsy syndrome	1.08e-06	1.96e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TH—epilepsy syndrome	1.08e-06	1.96e-05	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—AKT1—epilepsy syndrome	1.08e-06	1.95e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PLCB1—epilepsy syndrome	1.07e-06	1.95e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCR5—epilepsy syndrome	1.07e-06	1.94e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TH—epilepsy syndrome	1.07e-06	1.94e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCR5—epilepsy syndrome	1.06e-06	1.93e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCR5—epilepsy syndrome	1.06e-06	1.92e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.05e-06	1.91e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	1.05e-06	1.91e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCR5—epilepsy syndrome	1.05e-06	1.91e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—FGF2—epilepsy syndrome	1.04e-06	1.89e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—HTR2A—epilepsy syndrome	1.04e-06	1.89e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—HTR2A—epilepsy syndrome	1.04e-06	1.88e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—HTR2A—epilepsy syndrome	1.03e-06	1.86e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AGT—epilepsy syndrome	1.01e-06	1.84e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—RELA—epilepsy syndrome	1.01e-06	1.84e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TSC2—epilepsy syndrome	9.94e-07	1.8e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AGT—epilepsy syndrome	9.93e-07	1.8e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MTOR—epilepsy syndrome	9.92e-07	1.8e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—APOE—epilepsy syndrome	9.92e-07	1.8e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—POMC—epilepsy syndrome	9.91e-07	1.8e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TSC2—epilepsy syndrome	9.89e-07	1.79e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AGT—epilepsy syndrome	9.87e-07	1.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TSC2—epilepsy syndrome	9.85e-07	1.79e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AGT—epilepsy syndrome	9.84e-07	1.79e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—epilepsy syndrome	9.78e-07	1.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TSC2—epilepsy syndrome	9.76e-07	1.77e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AGT—epilepsy syndrome	9.75e-07	1.77e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—APOE—epilepsy syndrome	9.73e-07	1.77e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—RELA—epilepsy syndrome	9.69e-07	1.76e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—APOE—epilepsy syndrome	9.67e-07	1.76e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—APOE—epilepsy syndrome	9.64e-07	1.75e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—APOE—epilepsy syndrome	9.55e-07	1.73e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—HMOX1—epilepsy syndrome	9.54e-07	1.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KDR—epilepsy syndrome	9.53e-07	1.73e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MTOR—epilepsy syndrome	9.5e-07	1.72e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KDR—epilepsy syndrome	9.48e-07	1.72e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KDR—epilepsy syndrome	9.45e-07	1.71e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CAT—epilepsy syndrome	9.42e-07	1.71e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KDR—epilepsy syndrome	9.36e-07	1.7e-05	CbGpPWpGaD
Paroxetine—CHRM4—GPCR downstream signaling—AKT1—epilepsy syndrome	9.21e-07	1.67e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PRKCB—epilepsy syndrome	9.17e-07	1.66e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6ST—epilepsy syndrome	9.13e-07	1.66e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—CASP3—epilepsy syndrome	9.13e-07	1.66e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PRKCB—epilepsy syndrome	9.12e-07	1.66e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PRKCB—epilepsy syndrome	9.09e-07	1.65e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6ST—epilepsy syndrome	9.09e-07	1.65e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6ST—epilepsy syndrome	9.06e-07	1.64e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ALB—epilepsy syndrome	9.03e-07	1.64e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PRKCB—epilepsy syndrome	9.01e-07	1.63e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	8.99e-07	1.63e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6ST—epilepsy syndrome	8.97e-07	1.63e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—HMOX1—epilepsy syndrome	8.92e-07	1.62e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CAT—epilepsy syndrome	8.87e-07	1.61e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—JUN—epilepsy syndrome	8.86e-07	1.61e-05	CbGpPWpGaD
Paroxetine—CHRM5—GPCR downstream signaling—AKT1—epilepsy syndrome	8.82e-07	1.6e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CAT—epilepsy syndrome	8.8e-07	1.6e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—CASP3—epilepsy syndrome	8.74e-07	1.59e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	8.63e-07	1.57e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MMP9—epilepsy syndrome	8.62e-07	1.57e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AGT—epilepsy syndrome	8.57e-07	1.56e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ABCB1—epilepsy syndrome	8.56e-07	1.55e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—POMC—epilepsy syndrome	8.52e-07	1.55e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—epilepsy syndrome	8.52e-07	1.55e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—JUN—epilepsy syndrome	8.49e-07	1.54e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—APOE—epilepsy syndrome	8.4e-07	1.52e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—AKT1—epilepsy syndrome	8.36e-07	1.52e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—POMC—epilepsy syndrome	8.35e-07	1.52e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—POMC—epilepsy syndrome	8.31e-07	1.51e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—POMC—epilepsy syndrome	8.28e-07	1.5e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MMP9—epilepsy syndrome	8.26e-07	1.5e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—POMC—epilepsy syndrome	8.2e-07	1.49e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CCL2—epilepsy syndrome	8.17e-07	1.48e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CCL2—epilepsy syndrome	8.13e-07	1.48e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CCL2—epilepsy syndrome	8.11e-07	1.47e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CCL2—epilepsy syndrome	8.03e-07	1.46e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—epilepsy syndrome	8.03e-07	1.46e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—AKT1—epilepsy syndrome	8.01e-07	1.45e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—epilepsy syndrome	7.96e-07	1.44e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SRC—epilepsy syndrome	7.95e-07	1.44e-05	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PTGS2—epilepsy syndrome	7.9e-07	1.43e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ALB—epilepsy syndrome	7.77e-07	1.41e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—VEGFA—epilepsy syndrome	7.74e-07	1.41e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SRC—epilepsy syndrome	7.61e-07	1.38e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AGT—epilepsy syndrome	7.47e-07	1.36e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—VEGFA—epilepsy syndrome	7.42e-07	1.35e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGF2—epilepsy syndrome	7.39e-07	1.34e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGF2—epilepsy syndrome	7.35e-07	1.33e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGF2—epilepsy syndrome	7.32e-07	1.33e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—APOE—epilepsy syndrome	7.32e-07	1.33e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGF2—epilepsy syndrome	7.25e-07	1.32e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—epilepsy syndrome	7.22e-07	1.31e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AGT—epilepsy syndrome	7.04e-07	1.28e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AGT—epilepsy syndrome	6.98e-07	1.27e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—APOE—epilepsy syndrome	6.9e-07	1.25e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RELA—epilepsy syndrome	6.86e-07	1.24e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—APOE—epilepsy syndrome	6.84e-07	1.24e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RELA—epilepsy syndrome	6.82e-07	1.24e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RELA—epilepsy syndrome	6.8e-07	1.23e-05	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PTGS2—epilepsy syndrome	6.8e-07	1.23e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RELA—epilepsy syndrome	6.73e-07	1.22e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MTOR—epilepsy syndrome	6.73e-07	1.22e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MTOR—epilepsy syndrome	6.69e-07	1.21e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MTOR—epilepsy syndrome	6.67e-07	1.21e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MTOR—epilepsy syndrome	6.6e-07	1.2e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ALB—epilepsy syndrome	6.58e-07	1.19e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—epilepsy syndrome	6.29e-07	1.14e-05	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—AKT1—epilepsy syndrome	6.24e-07	1.13e-05	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—AKT1—epilepsy syndrome	6.21e-07	1.13e-05	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—AKT1—epilepsy syndrome	6.19e-07	1.12e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CASP3—epilepsy syndrome	6.19e-07	1.12e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CASP3—epilepsy syndrome	6.15e-07	1.12e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CASP3—epilepsy syndrome	6.13e-07	1.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—AKT1—epilepsy syndrome	6.13e-07	1.11e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CASP3—epilepsy syndrome	6.07e-07	1.1e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—JUN—epilepsy syndrome	6.01e-07	1.09e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—JUN—epilepsy syndrome	5.98e-07	1.08e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—JUN—epilepsy syndrome	5.96e-07	1.08e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—epilepsy syndrome	5.92e-07	1.08e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—JUN—epilepsy syndrome	5.9e-07	1.07e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—epilepsy syndrome	5.87e-07	1.07e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MMP9—epilepsy syndrome	5.85e-07	1.06e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MMP9—epilepsy syndrome	5.81e-07	1.06e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MMP9—epilepsy syndrome	5.8e-07	1.05e-05	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	5.76e-07	1.04e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MMP9—epilepsy syndrome	5.74e-07	1.04e-05	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ALB—epilepsy syndrome	5.73e-07	1.04e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—AKT1—epilepsy syndrome	5.67e-07	1.03e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—AKT1—epilepsy syndrome	5.64e-07	1.02e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—AKT1—epilepsy syndrome	5.62e-07	1.02e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—AKT1—epilepsy syndrome	5.57e-07	1.01e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ALB—epilepsy syndrome	5.4e-07	9.8e-06	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SRC—epilepsy syndrome	5.39e-07	9.78e-06	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SRC—epilepsy syndrome	5.36e-07	9.73e-06	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ALB—epilepsy syndrome	5.35e-07	9.72e-06	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SRC—epilepsy syndrome	5.34e-07	9.7e-06	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SRC—epilepsy syndrome	5.29e-07	9.61e-06	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—VEGFA—epilepsy syndrome	5.25e-07	9.53e-06	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—VEGFA—epilepsy syndrome	5.22e-07	9.48e-06	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—VEGFA—epilepsy syndrome	5.2e-07	9.45e-06	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—VEGFA—epilepsy syndrome	5.15e-07	9.36e-06	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PTGS2—epilepsy syndrome	5.01e-07	9.1e-06	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—AKT1—epilepsy syndrome	4.94e-07	8.97e-06	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—AKT1—epilepsy syndrome	4.73e-07	8.59e-06	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	4.72e-07	8.58e-06	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PTGS2—epilepsy syndrome	4.68e-07	8.5e-06	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—AKT1—epilepsy syndrome	3.97e-07	7.21e-06	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—AKT1—epilepsy syndrome	3.42e-07	6.2e-06	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—AKT1—epilepsy syndrome	3.35e-07	6.08e-06	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—AKT1—epilepsy syndrome	3.33e-07	6.05e-06	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—AKT1—epilepsy syndrome	3.32e-07	6.03e-06	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—AKT1—epilepsy syndrome	3.29e-07	5.97e-06	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—AKT1—epilepsy syndrome	2.89e-07	5.25e-06	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—AKT1—epilepsy syndrome	2.52e-07	4.57e-06	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—AKT1—epilepsy syndrome	2.37e-07	4.31e-06	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—AKT1—epilepsy syndrome	2.35e-07	4.27e-06	CbGpPWpGaD
